Successful Industrial GMP Manufacturing of RIBOXXIM, a Novel and Highly Potent Toll-like 3 Ligand for Immunotherapy of Cancer

Riboxx Logo

Radebeul, Germany & Lyon, France, September 12, 2017 / B3C newswire / -- RIBOXX PHARMACEUTICALS, a biotech company developing Toll-like-receptor (TLR) and RIG-I-like-Receptor (RLR) ligands, and ACCINOV, a pharmaceutical establishment for experimental drug products, today announced the successful industrial GMP manufacturing, including packaging and quality control of RIBOXXIM®, a novel and highly potent Toll-like Receptor 3 (TLR3)-ligand.

Manufacturing has been performed with the patented process TENPORA® of RIBOXX in full compliance with the EU GMP requirements, and with the GMP specifications of the experimental drug.

RIBOXXIM® is a proprietary drug substance of RIBOXX PHARMACEUTICALS. It activates the innate immune system to eliminate cancer cells as a validated approach in immuno-oncology with the historical TLR3 ligand poly(I:C) and its derivatives.

RIBOXXIM® has been validated in multiple pre-clinical studies for immunotherapy of cancer. It displays unique physico-chemical and biological properties, as well as optimal biodisponibility with increased stability to degradation in body fluids such as human plasma. RIBOXXIM® is stable as a drug product in liquid form for several months.

Prof. Dr. Jacques Rohayem, CEO and CSO of RIBOXX PHARMACEUTICALS declared: "We are proud to have reached this important milestone in the development of TLR3 ligands, with a unique, highly potent and stable drug product as a better alternative to poly(I:C) and its derivatives. RIBOXXIM® is available for pharmaceuticals companies or universities developing clinical applications in immuno-oncology and therapeutic vaccines."

André Dupont, President of ACCINOV declared: “We are proud to be the manufacturer of this innovative experimental drug. This achievement demonstrates the high flexibility of the ACCINOV model.”


About RIBOXX PHARMACEUTICALS
RIBOXX PHARMACEUTICALS is a biotech company developing proprietary Toll-like-receptor (TLR) ligands and RIG-I-like-Receptor (RLR) ligands for applications in immune-oncology and therapeutic vaccines. RIBOXX IP portfolio includes 18 PCT patent families so far, with 8 PCT patents granted in EU and/or Japan.


Contact

Prof. Dr. med. Jacques ROHAYEM
CEO & CSO
RIBOXX PHARMACEUTICALS
www.riboxx-pharma.com
+49 351 8336010
This email address is being protected from spambots. You need JavaScript enabled to view it.

The development of the industrial GMP manufacturing of RIBOXXIM was supported by the Sächsische Aufbaubank (EFRE Program FKZ 100228307) from the government of Saxony (Germany).

Cookies make it easier for us to provide you with our services. With the usage of our services you permit us to use cookies.